Fig. 5
From: A functional role of LEFTY during progesterone therapy for endometrial carcinoma
Association of LEFTY with GSK-3β during progesterone therapy for Em Cas. a Left: staining by hematoxylin and eosin (HE) and IHC for the indicated molecules in Em Ca cases with good response to progesterone therapy. Original magnification, ×200. Middle and right: IHC scores for pGSK-3β and its relation to therapeutic periods (middle) and therapeutic efficacy (TE) (right). B, before progesterone therapy; m, months. b Western blot analysis for the indicated molecules in Ishikawa cells treated with 10−6 or 10−8 M medroxyprogesterone 17-acetate (MPA) for 24 h. Et, ethanol. c Western blot analysis for the indicated molecules in Ishikawa and Hec251 cells following treatment with 40 mM LiCl for the times shown. Note the slower migrating bands of endogenous LEFTY (indicated by asterisk), probably due to phosphorylation of the protein. d Western blot analysis for LEFTY in Ishikawa cells following treatment with a combination of 40 mM LiCl for 24 h and 10 μM MG132 for 5 h. Note the slower migrating bands of endogenous LEFTY (indicated by asterisk)